Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus Vaccines

Durbin, Anna P.; Karron, Ruth A.
December 2003
Clinical Infectious Diseases;12/15/2003, Vol. 37 Issue 12, p1668
Academic Journal
Respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are leading causes of viral lower respiratory tract illness in children and in high-risk adult populations. Despite decades of research, licensed vaccines for RSV and hPIVs do not exist. Recently, however, genetically engineered live attenuated RSV and hPIV candidate vaccines have been generated, several of which are already being evaluated in clinical trials. Recombinant technology allows candidate vaccines to be "fine-tuned" in response to clinical data, which should hasten the development of vaccines against these important respiratory pathogens.


Related Articles

  • Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific. Levitz, Ruth; Wattier, Rachel; Phillips, Pamela; Solomon, Alexandra; Lawler, Jessica; Lazar, Isaac; Weibel, Carla; Kahn, Jeffrey S. // Virology Journal;2012, Vol. 9 Issue 1, p190 

    Background: Respiratory syncytial virus (RSV) is the major respiratory pathogen of infants and young children. During each seasonal epidemic, multiple strains of both subgroup A and B viruses circulate in the community. Like other RNA viruses, RSV genome replication is prone to errors that...

  • Fixing a failed vaccine. Varga, Steven M. // Nature Medicine;Jan2009, Vol. 15 Issue 1, p21 

    The article discusses the reasons behind the failure of the formalin-inactivated respiratory syncytial virus (RSV) vaccine. According to researchers M.F. Delgado and others, inactivated forms of RSV do not sufficiently activate various pattern recognition receptors, molecules important for the...

  • cervical cancer vaccine deception. Bohackyj, Patricia // Natural Health & Vegetarian Life;Autumn2007, p52 

    The article criticizes the clinical testing of cervical cancer vaccines, Gardasil and Cervarix, conducted by the vaccine manufacturers Merck and GlaxoSmithKline. Those who participated in the studies developed headache, nausea and autoimmune problems, among others. The author notes that there...

  • An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. van Remmerden1, Yvonne; Fang Xu; van Eldik, Mandy; Heldens, Jacco G. M.; Huisman, Willem; Widjojoatmodjo, Myra N. // Virology Journal;2012, Vol. 9 Issue 1, p253 

    Background: Virus neutralizing antibodies against respiratory syncytial virus (RSV) are considered important correlates of protection for vaccine evaluation. The established plaque reduction assay is time consuming, labor intensive and highly variable. Methods: Here, a neutralization assay based...

  • Inhibition of respiratory viruses by nasally administered siRNA. Bitko, Vira; Musiyenko, Alla; Shulyayeva, Olena; Barik, Sailen // Nature Medicine;Jan2005, Vol. 11 Issue 1, p50 

    Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that...

  • Protecting the Family to Protect the Child: Vaccination Strategy Guided by RSV Transmission Dynamics. Graham, Barney S. // Journal of Infectious Diseases;Jun2014, Vol. 209 Issue 11, p1679 

    The author discusses the impact of the Respiratory syncytial virus (RSV) with its impact on households, and the vaccination strategy guided by the RSV transmission dynamics. Topics discussed include the transmission of an infant's first RSV infection being attributed to household's school-age...

  • Proof of principle for epitope-focused vaccine design. Correia, Bruno E.; Bates, John T.; Loomis, Rebecca J.; Baneyx, Gretchen; Carrico, Chris; Jardine, Joseph G.; Rupert, Peter; Correnti, Colin; Kalyuzhniy, Oleksandr; Vittal, Vinayak; Connell, Mary J.; Stevens, Eric; Schroeter, Alexandria; Chen, Man; MacPherson, Skye; Serra, Andreia M.; Adachi, Yumiko; Holmes, Margaret A.; Li, Yuxing; Klevit, Rachel E. // Nature;3/13/2014, Vol. 507 Issue 7491, p201 

    Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such...

  • Call for vaccine to stem rising tide of RSV admissions. Gough, Rob // Pulse;5/6/2002, Vol. 62 Issue 18, p16 

    Reports that experts are calling for a vaccine against respiratory syncytial virus (RSV) after a study revealed a rise in the number of hospitalizations caused by the disease. Rate of RSV-related admissions; Direct health economic bill for RSV; Annual rate of RSV-proven hospitalizations in infants.

  • Sinovac: Panflu on track in pandemic flu.  // PharmaWatch: Biotechnology;May2006, Vol. 5 Issue 5, p5 

    The article reports on the completion of the immunization schedule in the phase I pandemic influenza vaccine trial of Sinovac Biotech Co. Ltd. in 2006. The company has announced that all 120 volunteers in a phase I clinical trial of its avian influenza vaccine Panflu have completed the two-shot...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics